The presence of mTOR activity probably indicates that the inclusion of mTOR inhibition in the therapy of Hodgkin-lymphomas may be feasible and beneficial, especially when standard protocols are ineffective, and it may also allow dose reduction in order to decrease late treatment toxicity.
Moreover, mTORC1 may be a potential therapeutic target in HL, especially when commonly used protocols prove ineffective, and may also allow dose reduction of chemotherapeutic drugs in order to decrease late toxicity without diminishing treatment efficacy.
In addition, the capacity of IMRT to limit dose to normal tissue structures may also allow dose escalation and differential dose painting, thereby accomplishing 'in-field tumour boosting' (Butler et al, 1999).
The combination of mTOR inhibitors with other agents will probably offer the highest efficiency for achieving the best clinical response, and may also allow dose reduction in order to decrease late treatment toxicity in these cases.
While it remains difficult to evaluate the amount of antigen to which the immune system is actually exposed, this study supports the experimental evidence from many studies that TC vaccination may in fact allow dose sparing with equivalent T cell responses, self-administration, and immune enhancement, even in elderly patients with less responsive immune systems [85], [86].
Raster-scanned carbon ion therapy with highly conformal dose distributions may allow higher doses at comparable or reduced side-effects.
Our findings support that switching IV to oral administration of alfacalcidol during hemodialysis sessions may lead to a similar control of SHPT with lower doses of activated vitamin D. This is a good strategy for optimizing compliance and may allow a dose reduction because of a greater efficacy to suppress PTH.
Thus, the sheep data (Figures 7 and 8) suggest that ASC may allow the dose of adrenergic drug to be dropped more than ten fold, retaining therapeutic efficacy, but also reducing systemic side effects such as the increased blood pressure, increased heart rate, nervousness, and sleeplessness that often accompany adrenergic inhaler use.
Such a combination may allow less dose of each drug, and therefore decrease side effects.
Low calcaemic vitamin D analogues, such as seocalcitol (EB1089), have demonstrated antiproliferative effects in preclinical models and may allow improved dose delivery and antitumour activity.
